Search Clinical Trials
Sponsor Condition of Interest |
---|
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Advanced Cancer
Metastatic Cancer
Ovarian Cancer
Primary Peritoneal Cancer
Fallopian Tube Cancer
This clinical trial is evaluating a drug called ART0380 in participants with advanced or
metastatic solid tumors. The main goals of this study are to:
- Find the recommended dose of ART0380 that can be given safely to participants alone
and in combination with gemcitabine or irinotecan1 expand
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: - Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan - Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan - Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan Type: Interventional Start Date: Dec 2020 |
Virtual Reality-Base Intelligent Orientation and Mobility Specialists Trial
University of Alabama at Birmingham
Low Vision, Both Eyes
The human subject research is a randomized, controlled training trial that tests the
effectiveness of three Virtual Reality-based Intelligent Orientation and Mobility
Specialists (VR-IOMSs) in teaching orientation and mobility (O&M) task skills to low
vision patients. It will be conducted on two si1 expand
The human subject research is a randomized, controlled training trial that tests the effectiveness of three Virtual Reality-based Intelligent Orientation and Mobility Specialists (VR-IOMSs) in teaching orientation and mobility (O&M) task skills to low vision patients. It will be conducted on two sites, University of Alabama at Birmingham (UAB) and Alabama Institute for Deaf and Blind (AIDB). The same protocol will be used on both sites. UAB will be the sIRB for the trial. Three O&M tasks will be studied, timing to cross a signalized street using the near lane parallel traffic surge skill, timing to cross an uncontrolled street using the traffic gap judgment skill and learning outdoor numbering system. A VR-IOMS will be develop for each task. The training does not involve research subjects walking into street traffic. Low vision subjects who have difficulties with these O&M tasks due to their impaired vision will be randomized into three groups, learning the task from a VR-IOMS (experimental group), from a human Certified Orientation & Mobility Specialist (COMS) in real streets (active control group) and not learning the task but spending the same amount of time watching low vision education videos (placebo group). All subjects will be evaluated by COMSs in real streets around the two study sites before training (pre-training), within 3 days after the completion of training (post-training) and 3 months after the completion of training (follow up). Their ability to perform the O&M tasks will be assess quantitatively using objective methods. COMSs who conduct these evaluations will be blinded for subject training assignment. The primary outcome measure is the training effect, the difference in task performance between the pre-training and post-training real street evaluations. The training effects of the 3 groups will be compared to determine the training effectiveness of the VR-IOMS relative to human COMS. Secondary outcome measures include the retainment of the training effect. Objective assessment of the VR-IOMS training process and trainee subjective evaluation of the VR-IOMS training will also be analyzed. Type: Interventional Start Date: Aug 2023 |
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
University of Utah
Autoimmune Encephalitis
Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with
anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line"
immunomodulatory therapies provided as standard-of-care, and either inebilizumab
(investigational agent) or placebo. expand
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo. Type: Interventional Start Date: Mar 2022 |
NTX-301 in MDS/AML
University of Alabama at Birmingham
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has
shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301
in patients with myeloid malignancies. expand
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies. Type: Interventional Start Date: Jan 2021 |
The Biosonographic Index
University of Alabama at Birmingham
Acute Kidney Injury
In this exploratory study we explore the use of Shear Wave Elastography to differentiate
between Acute Kidney Injury after vascular surgery and among the healthy population. expand
In this exploratory study we explore the use of Shear Wave Elastography to differentiate between Acute Kidney Injury after vascular surgery and among the healthy population. Type: Interventional Start Date: Jan 2020 |
Epidemiology of Silent and Overt Strokes in Sickle Cell Disease
Vanderbilt University Medical Center
Anemia, Sickle Cell
Sickle Cell Disease
Stroke
Sickle Cell Thalassemia
Sickle Cell-Beta0-Thalassemia
Sickle Cell Disease (SCD) is a rare disease occurring in an estimated 100,000
individuals, often poor and underserved, in the US. Silent and overt strokes contribute
significantly to morbidity in adults with SCD, resulting in functional impairment,
challenges with school and job performance, and pr1 expand
Sickle Cell Disease (SCD) is a rare disease occurring in an estimated 100,000 individuals, often poor and underserved, in the US. Silent and overt strokes contribute significantly to morbidity in adults with SCD, resulting in functional impairment, challenges with school and job performance, and premature death. Five NIH-funded randomized controlled trials have identified therapies to prevent silent and overt strokes in children with SCD, including monthly blood transfusion therapy (for preventing initial and recurrent strokes) and hydroxyurea (for preventing initial strokes). Despite the observation that at least 99% of children with SCD in high-income countries reach adulthood, and approximately 60% of adults will experience one or more strokes (~50% with silent strokes and ~10% with overt strokes), no stroke trials have established therapeutic approaches for adults with SCD. For adults with SCD, inadequate evidence-based guidelines exist for secondary stroke prevention strategies. Applying stroke prevention strategies in children may not be effective for stroke prevention in adults with SCD, particularly given the high rate of co-morbidities. Identifying subgroups of adults with SCD and higher incidence coupled with the contribution of established stroke risk factors in the general population (smoking, diabetes, obesity, renal disease) will provide the requisite data required for the first-ever phase III clinical trials focused on secondary stroke prevention in adults. Type: Observational Start Date: Jun 2017 |
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
University of Alabama at Birmingham
Pediatric Cancer
This study will explore the potential benefits of a virtual reality gaming program that
focuses on mindfulness and exercise among pediatric cancer rehabilitation patients. The
program will last 8 weeks outside of the hospital. Participants will start immediately in
the hospital (immediate start gro1 expand
This study will explore the potential benefits of a virtual reality gaming program that focuses on mindfulness and exercise among pediatric cancer rehabilitation patients. The program will last 8 weeks outside of the hospital. Participants will start immediately in the hospital (immediate start group) or wait 8 weeks after hospital discharge to start the program (waitlist control group). Type: Interventional Start Date: Jun 2024 |
Early Intervention to Promote Cardiovascular Health of Mothers and Children
JHSPH Center for Clinical Trials
Cardiovascular Health
Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) is a
cluster randomized clinical trial, funded by the National Heart Lung & Blood Institute.
The study is designed to test the effectiveness of home visiting intervention to promote
cardiovascular health and reduce1 expand
Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) is a cluster randomized clinical trial, funded by the National Heart Lung & Blood Institute. The study is designed to test the effectiveness of home visiting intervention to promote cardiovascular health and reduce disparities in maternal and early childhood cardiovascular health. Sites, in partnership with evidence-based home visiting programs, are recruiting 6400 participants in total (i.e., 3200 parent-dyads which includes 3200 parents and 3200 children) from diverse community settings with a high burden of cardiovascular disease risk factors. Type: Interventional Start Date: Jun 2024 |
Predicton of Sepsis Recovery Performance Subtypes Pilot Study
University of Alabama at Birmingham
Sepsis
This study addresses critically ill sepsis patients' current literature reports of
ongoing post-hospital discharge weakness and hospital readmissions. This study is aimed
at capture and interpretation of a complex set of tests, administered during a subject's
sepsis functional recovery trajectory,1 expand
This study addresses critically ill sepsis patients' current literature reports of ongoing post-hospital discharge weakness and hospital readmissions. This study is aimed at capture and interpretation of a complex set of tests, administered during a subject's sepsis functional recovery trajectory, particularly capturing hospital readmission's effects on survivors' physical function recovery. Type: Observational Start Date: Jul 2023 |
The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.
University of Alabama at Birmingham
Preeclampsia
Gestational Hypertension
Hypertensive Disorder of Pregnancy
The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure
to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong
pregnancy. expand
The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy. Type: Interventional Start Date: Feb 2023 |
Cognitive Remediation Intervention to Prepare for Transition of Care
University of Alabama at Birmingham
Sickle Cell Disease
Cognitive Impairment
Adolescent Behavior
Self Efficacy
Health-Related Behavior
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the
Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention
to prepare adolescents with sickle cell disease for transition of care. expand
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care. Type: Interventional Start Date: Jul 2022 |
CARBON: UAB Cardiovascular Research Biobank
University of Alabama at Birmingham
Natriuretic Peptides
Cardiovascular Diseases
Hypertension
Diabetes
Obesity
The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains
biological materials, such as DNA samples, in addition to health and personal information
on a large number of people over time. It will be set up so that it can be used in the
future as a resource for researchers und1 expand
The UAB Cardiovascular Research Biobank (CARBON) will be a resource that contains biological materials, such as DNA samples, in addition to health and personal information on a large number of people over time. It will be set up so that it can be used in the future as a resource for researchers undertaking a wide range of medical research. Type: Observational Start Date: Jan 2022 |
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Ep1
Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoproliferative Disorder
EBV-Related PTLD
EBV Related Non-Hodgkin's Lymphoma
EBV-Positive DLBCL, NOS
EBV Associated Lymphoma
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with
valganciclovir in patients with relapsed/refractory EBV-positive lymphomas expand
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas Type: Interventional Start Date: May 2021 |
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Duke University
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started
recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018,
the registry expanded to include recruitment of participants with other chronic fibrosing
interstitial lung diseases (ILDs) wit1 expand
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects. Type: Observational [Patient Registry] Start Date: Jun 2014 |
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
University of Alabama at Birmingham
Recurrent Acute Pancreatitis
This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in
patients with recurrent acute pancreatitis. expand
This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute pancreatitis. Type: Interventional Start Date: Jun 2024 |
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Al1
University of Alabama at Birmingham
Frontal Fibrosing Alopecia
The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in
the treatment of frontal fibrosing alopecia (FFA). expand
The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA). Type: Interventional Start Date: Apr 2024 |
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytos1
University of Alabama at Birmingham
Lymphoma
Hemophagocytic Lymphohistiocytoses
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in
patients with lymphoma to identify possible therapeutic strategies to improve overall
survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis. expand
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis. Type: Observational Start Date: May 2023 |
A New Training to Enhance Physical Activity in Adolescents With Cerebral Palsy
University of Alabama at Birmingham
Cerebral Palsy
Muscle Disorder
Physical Disability
Posture Disorders in Children
Spina Bifida
The purpose of this research study is to test the feasibility and response of a new
exercise protocol on improving physical activity in adolescents with cerebral palsy. expand
The purpose of this research study is to test the feasibility and response of a new exercise protocol on improving physical activity in adolescents with cerebral palsy. Type: Interventional Start Date: Aug 2023 |
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Weill Medical College of Cornell University
Emphysema
HIV
The purpose of this study is to determine if doxycycline will reduce progression of
emphysema in people living with HIV.
The secondary objectives are to examine the effects of doxycycline on change in quantity
of emphysema, six minute walk distance, patient reported outcomes, ratio of forced
expir1 expand
The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections. Type: Interventional Start Date: Aug 2022 |
Equity in Prevention and Progression of Hypertension by Addressing Barriers to Nutrition and Physic1
University of Alabama at Birmingham
Prehypertension
Hypertension
Blood Pressure
The goal of this study is to test an intervention to prevent high blood pressure among
rural, Black adults living in Alabama. Black adults in this region have one of the
highest rates of high blood pressure in the US. Eating fruits and vegetables and
exercising daily lowers the chance of getting hi1 expand
The goal of this study is to test an intervention to prevent high blood pressure among rural, Black adults living in Alabama. Black adults in this region have one of the highest rates of high blood pressure in the US. Eating fruits and vegetables and exercising daily lowers the chance of getting high blood pressure. Many problems get in the way of eating a healthy diet and exercising like a lack of grocery stores with fresh foods, few gyms, little money, lack of transportation, and limited support for keeping healthy habits. One place where many Black adults in rural Alabama meet weekly and feel supported is their church. The investigators will connect with 30 churches in rural Alabama. The investigators plan to hold health fairs to find 12 Black adults from each church with blood pressure that is higher than normal but not high enough to need blood pressure lowering medications. The investigators will randomly select 15 churches to get group health education and tablets to access online cooking shows and exercise classes. Adults in the other 15 churches will get support from a health coach over the telephone to help set and meet diet and physical activity goals as well as the group health education and tablets to access online cooking shows and exercise classes. In this study, the investigators will ask church members to sign up to be a health coach. These 15 churches will also get money to help bring healthy foods and/or physical activity opportunities to their communities. The investigative team will train 2 to 3 of their church members to learn how to coach others to eat more healthy food and be more physically active. This study answers two questions. 1) Will this intervention designed to reduce barriers to a healthy lifestyle lower blood pressure among rural, Black adults? 2) Can churches and participants complete the whole two-year study, and can the intervention be used in other communities in a cost-effective way to improve blood pressure? This project will add to the health equity mission of the American Heart Association by finding out if an intervention using health coaches lowers blood pressure among rural Black adults. Type: Interventional Start Date: Aug 2022 |
Gain of Keratinized Mucosa Around Teeth and Dental Implants Using a Combination of Strip Gingival G1
University of Alabama at Birmingham
Gingival Recession
Lack of Keratinized Attached Peri-implant Mucosa
Thin Gingiva
This study is to compare the two techniques to achieve change in the tissue quality at
areas of lack of Keratinized Tissue (KT) using soft tissue grafting with autogenous graft
material (Free Gingival Graft)(FGG) vs Strip gingival graft with acellular dermal matrix
(ADM) (SGG+ADM). expand
This study is to compare the two techniques to achieve change in the tissue quality at areas of lack of Keratinized Tissue (KT) using soft tissue grafting with autogenous graft material (Free Gingival Graft)(FGG) vs Strip gingival graft with acellular dermal matrix (ADM) (SGG+ADM). Type: Interventional Start Date: Sep 2021 |
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
University of Alabama at Birmingham
Primary Open Angle Glaucoma
Mobility refers to a person's purposeful movement through the environment from one place
to another and can be conceptualized as a continuum from bed bound (immobility) on one
extreme to making excursions to distant locations on the other extreme. Primary
open-angle glaucoma (POAG) is a chronic, pr1 expand
Mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. Primary open-angle glaucoma (POAG) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. Older adults with POAG have an increased risk for motor vehicle collisions and falls. Moreover, existing studies suggest that patients with POAG exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. While these disturbances likely influence mobility, there has been little research directly assessing the impact of POAG on mobility. This study will assess the impact of POAG on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting. Type: Observational Start Date: Jun 2019 |
Comparing Two Methods to Follow Patients With Pancreatic Cysts
ECOG-ACRIN Cancer Research Group
Pancreatic Carcinoma
The purpose of this study is to compare the two approaches for monitoring pancreatic
cysts. The study doctors want to compare more frequent monitoring vs less frequent
monitoring in order to learn which monitoring method leads to better outcome for patients
with pancreatic cysts. expand
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts. Type: Interventional Start Date: Jun 2020 |
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smo1
ECOG-ACRIN Cancer Research Group
Smoldering Plasma Cell Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or
without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in
chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the
growth of tumor cells, either by kill1 expand
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma. Type: Interventional Start Date: Sep 2019 |
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic F1
SpliSense Ltd.
Cystic Fibrosis
The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with
cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF
with a specific mutation.
The purpose of this research study is to:
- test the safety and effectiveness of multiple do1 expand
The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation. The purpose of this research study is to: - test the safety and effectiveness of multiple doses of the study drug, SPL84 - test how multiple doses of the drug are processed by the body Researchers will compare drug SPL84 to a placebo (a look-alike substance that contains no drug) to see if drug SPL84 is safe and if it works to treat CF. Participants will: Take drug SPL84 or a placebo by inhalation every week for 9 weeks months Visit the clinic approximately 14 times over 17.5 weeks for checkups and tests Type: Interventional Start Date: Jul 2024 |
- Previous
- Next